Zebra Capital Management LLC Takes $50,000 Position in Abeona Therapeutics Inc (NASDAQ:ABEO)
Zebra Capital Management LLC bought a new stake in Abeona Therapeutics Inc (NASDAQ:ABEO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 15,185 shares of the biopharmaceutical company’s stock, valued at approximately $50,000.
Several other institutional investors also recently added to or reduced their stakes in ABEO. Victory Capital Management Inc. boosted its stake in Abeona Therapeutics by 144.5% during the 4th quarter. Victory Capital Management Inc. now owns 11,474 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 6,782 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Abeona Therapeutics in the 4th quarter valued at $26,000. Point72 Hong Kong Ltd bought a new position in Abeona Therapeutics in the 4th quarter worth $34,000. Voloridge Investment Management LLC bought a new position in Abeona Therapeutics in the 3rd quarter worth $86,000. Finally, SG Americas Securities LLC raised its holdings in Abeona Therapeutics by 58.1% in the 3rd quarter. SG Americas Securities LLC now owns 44,170 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 16,234 shares during the period.
ABEO traded down $0.07 on Thursday, hitting $2.10. 1,399,710 shares of the company were exchanged, compared to its average volume of 1,809,397. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.42 and a current ratio of 3.42. The firm has a fifty day simple moving average of $2.80 and a two-hundred day simple moving average of $2.78. The stock has a market capitalization of $173.10 million, a PE ratio of -1.37 and a beta of 1.50. Abeona Therapeutics Inc has a 12 month low of $1.35 and a 12 month high of $8.41.
ABEO has been the topic of several recent research reports. Cantor Fitzgerald began coverage on Abeona Therapeutics in a report on Tuesday, December 10th. They issued a “hold” rating and a $4.00 price target on the stock. ValuEngine upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, December 3rd. Mizuho reaffirmed a “hold” rating and set a $4.00 price target on shares of Abeona Therapeutics in a report on Tuesday, December 10th. Royal Bank of Canada reduced their price target on shares of Abeona Therapeutics from $14.00 to $11.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 18th. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Monday. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $6.50.
Abeona Therapeutics Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Article: What is the price-to-earnings growth (PEG) ratio?
Want to see what other hedge funds are holding ABEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abeona Therapeutics Inc (NASDAQ:ABEO).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.